ARCH Venture Management LLC Purchases Shares of 4,120,053 Maze Therapeutics, Inc. $MAZE

Key Points

• ARCH Venture Management LLC acquired 4,120,053 shares of Maze Therapeutics, representing about 22% of its investment portfolio, valued at approximately $45.36 million.
• Research firms have given Maze Therapeutics a consensus rating of "Buy" with various price targets ranging from $17.00 to $34.00 as firms initiate and upgrade coverage.
• The stock performance shows a current price of $15.32, with a 52-week range between $6.71 and $19.19.

ARCH Venture Management LLC purchased a new stake in shares of Maze Therapeutics, Inc. (NASDAQ:MAZE - Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 4,120,053 shares of the company's stock, valued at approximately $45,362,000. Maze Therapeutics accounts for approximately 22.0% of ARCH Venture Management LLC's investment portfolio, making the stock its 2nd largest position. ARCH Venture Management LLC owned 9.41% of Maze Therapeutics as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. New York State Common Retirement Fund purchased a new position in shares of Maze Therapeutics in the first quarter valued at about $25,000. Corebridge Financial Inc. bought a new stake in Maze Therapeutics during the first quarter worth approximately $48,000. Deutsche Bank AG bought a new stake in Maze Therapeutics during the first quarter worth approximately $98,000. Nuveen LLC bought a new stake in Maze Therapeutics during the first quarter worth approximately $125,000. Finally, Bank of New York Mellon Corp bought a new position in shares of Maze Therapeutics during the first quarter valued at approximately $190,000.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on the company. BTIG Research began coverage on Maze Therapeutics in a research note on Tuesday. They issued a "buy" rating and a $30.00 price objective on the stock. Wall Street Zen upgraded Maze Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, August 16th. HC Wainwright initiated coverage on Maze Therapeutics in a research note on Wednesday, July 23rd. They set a "buy" rating and a $34.00 price objective for the company. Finally, Wedbush initiated coverage on Maze Therapeutics in a research report on Tuesday, July 8th. They set an "outperform" rating and a $17.00 target price on the stock. Two equities research analysts have rated the stock with a Strong Buy rating and six have given a Buy rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Buy" and an average target price of $26.33.

Maze Therapeutics Stock Performance

NASDAQ:MAZE opened at $15.32 on Wednesday. The company has a fifty day simple moving average of $14.35 and a two-hundred day simple moving average of $11.95. Maze Therapeutics, Inc. has a 52 week low of $6.71 and a 52 week high of $19.19.

Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last issued its earnings results on Tuesday, August 12th. The company reported ($0.77) EPS for the quarter, topping analysts' consensus estimates of ($0.79) by $0.02.

Maze Therapeutics Profile

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.